Lee, J. Ryu, H. Keum, G. Yoon, Y. J. Kowall, N. W. Ryu, H. 2024-01-20T09:02:00Z 2024-01-20T09:02:00Z 2021-09-05 2014-09 0929-8673 https://pubs.kist.re.kr/handle/201004/126388 Amyotrophic lateral sclerosis (ALS) is an adult-onset motor neuron disease characterized by degeneration of motor neuron and glial activation followed by the progressive muscle loss and paralysis. Numerous distinct therapeutic interventions have been examined but currently ALS does not have a cure or an efficacious treatment for the disorder. Glutamate-induced excitotoxicity, inflammation, mitochondrial dysfunction, oxidative stress, protein aggregation, transcription deregulation, and epigenetic modifications are associated with the pathogenesis of ALS and known to be therapeutic targets in ALS. In this review, we discuss translational pharmacological studies targeting epigenetic components to ameliorate ALS. Understanding of the epigenetic mechanisms will provide novel insights that will further identify potential biological markers and therapeutic approaches for treating ALS. A combination of treatments that modulate epigenetic components and multiple targets may prove to be the most effective therapy for ALS. English Bentham Science Publishers Therapeutic Targeting of Epigenetic Components in Amyotrophic Lateral Sclerosis (ALS) Article 10.2174/0929867321666140706131825 1 Current Medicinal Chemistry, v.21, no.31, pp.3576 - 3582 Current Medicinal Chemistry 21 31 3576 3582 N scie scopus 000341969600005 2-s2.0-84914686005 Biochemistry & Molecular Biology Chemistry, Medicinal Pharmacology & Pharmacy Biochemistry & Molecular Biology Pharmacology & Pharmacy Article HISTONE DEACETYLASE INHIBITORS SPINAL MUSCULAR-ATROPHY L-ALANINE BMAA MOUSE MODEL HUNTINGTONS-DISEASE PROLONGS SURVIVAL SODIUM PHENYLBUTYRATE SUPEROXIDE-DISMUTASE VALPROIC ACID LINKED SOD1 Amyotrophic lateral sclerosis epigenetic components HDAC inhibitor motor neuron transcription therapeutics